Your session is about to expire
← Back to Search
Chemotherapy + Immunotherapy for Esophageal Cancer
Study Summary
This trial is testing a combination of atezolizumab, oxaliplatin, and fluorouracil to treat patients with esophageal or gastroesophageal cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 3 trial • 1225 Patients • NCT02008227Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer is not classified as T1aN0, T4b, or M1.I tested negative for HBsAg and positive for HBcAb.My white blood cell count is healthy without needing medication.I do not have uncontrolled diabetes, heart issues, high blood pressure, or mental health conditions that would prevent my participation.I have active tuberculosis.My primary tumor is actively bleeding and needs radiation.My calcium levels are not higher than normal and I don't have symptoms of high calcium.My hemoglobin level is at least 9 g/dL, possibly after a transfusion.I haven't had major surgery in the last 4 weeks and don't expect to need one during the study.I have an active hepatitis B infection.My cancer is in an early stage but has spread to nearby lymph nodes.I am allergic to oxaliplatin or 5-FU medications.My blood thinner medication dose has been stable.I haven't taken antibiotics for treatment in the last 2 weeks, but I may be on preventive antibiotics.I have a history of certain lung conditions or signs of lung inflammation on a recent CT scan.My skin condition is mild, covers less than 10% of my body, and hasn't needed strong treatments in the last year.I am using effective birth control while on treatment.I haven't taken strong immune system medications in the last 2 weeks.I have an autoimmune disease but it's either hypothyroidism treated with hormones or controlled type 1 diabetes.I am healthy enough to undergo surgery.My blood clotting tests are within normal limits and I'm not on blood thinners.I have an active hepatitis C infection confirmed by tests.I have previously been treated with specific immune therapies.My platelet count is at least 100,000 without needing a transfusion.My cancer has spread to nearby organs and there's a risk of developing a fistula.I do not have any health conditions that would make it unsafe for me to take a new drug.I haven't had any cancer, except some low-risk types, in the last 5 years.I am not pregnant, have tested negative for pregnancy, and am not breastfeeding.I haven't taken any immune-boosting drugs in the last 4 weeks or longer.My kidney function, measured by creatinine levels, is within the required range.I have had a stem cell or organ transplant in the past.My cancer is identified as squamous cell carcinoma.I understand and can follow the study's requirements.I have not had a severe infection or been hospitalized for one in the last 4 weeks.I can provide a tumor sample for PDL-1 testing.I experience significant numbness or pain in my hands or feet.My cancer is a type of esophageal or gastroesophageal adenocarcinoma.I have not had any chemotherapy or radiation therapy before.I am fully active or can carry out light work.I do not have serious heart problems like recent heart attacks or unstable heart conditions.I have not received a live vaccine in the last 4 weeks and do not plan to during the study.
- Group 1: Cohort 2- Atezolizumab plus and Tiragolumab with Oxaliplatin and 5-fluorouracil (5-FU)
- Group 2: Cohort 1-Atezolizumab combination with Oxaliplatin and 5-fluorouracil (5-FU)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many people are included in this clinical trial?
"That is correct, the clinical trial listed on clinicaltrials.gov is open and presently looking for 30 individuals to participate at 1 location."
Are there still open spots for people who want to participate in this research?
"Yes, this is an active study that has updated their recruitment information as recently as October 5th, 2022. 30 individuals are needed to participate at a single location."
Atezolizumab is most commonly used to treat what condition?
"Atezolizumab is primarily used to fight small cell lung cancer, but can also assist patients with malignant neoplasms, superficial basal cell carcinoma, and rectal carcinoma."
Could you tell me if Atezolizumab has been studied before?
"Atezolizumab is being studied in 860 active clinical trials, with 246 of those in Phase 3. While there is a large concentration of these studies in Guangzhou, Guangdong, there are 39466 total locations for these trials."
Has Atezolizumab been linked with any adverse health effects?
"Atezolizumab is a medication that, while having some clinical data supporting its safety, has not yet been proven effective. Our team believes it deserves a score of 2."
Share this study with friends
Copy Link
Messenger